Member login

Forgot Password?

By using the members area you have already agreed to share your personal information with the BGMA/BBA so that you can access the members materials. We will store your details only as long as you are a member. Your personal information will not be shared any affiliated companies or third parties. For more information about our Privacy Policy, click here.

Return to login
Back to News index

Paul Burden elected BGMA vice-chair

  • UK Vice President Rx for Stada Thornton & Ross to take up association leadership role.

(Tuesday 11th June) The British Generic Manufacturers Association (BGMA), the representative trade association for off-patent medicines has elected Paul Burden as its next vice-chair.

Paul, who is the current UK Vice President Rx for Stada Thornton & Ross, has 25 years’ experience in the off-patent sector.

Prior to his current position, he has held a variety of commercial roles with companies such as Arrow Generics, Mylan, Teva and Advanz.

At an association level he has been involved with the BGMA since 2011 including chairing the economic and commercial working group for four years. He has helped shape the BGMA’s priorities and position on topics such as generic pricing, falsified medicines directive, economic data, voluntary schemes, and supply chain issues.

Paul Burden said: “Off-patent medicines represent the vast majority of prescription products taken by NHS patients, so it is vitally important their contribution is properly recognised by clinicians and policymakers alike. I am looking forward to further reinforcing the association’s position as a critical partner to the Department of Health & Social Care as well as the NHS, in shaping solutions that deliver value and improved patient access. It is vital to ensure the UK is able to benefit from a thriving, competitive and sustainable off-patent pharma sector.”

Mark Samuels, Chief Executive of the BGMA, said: “We are very fortunate to be able to call upon the experience of someone like Paul who has held so many senior positions in our sector. His input as vice-chair will be vital in the next phase of the association’s engagement. This will include a focus on ensuring the UK remains a compelling supply market for manufacturers and that patients are able to access the right medicine at the right time.”

Paul will succeed current BGMA chair Diane DiGangi-Trench when her tenure completes.


For further information about the BGMA please contact Jeremy Durrant on 07792918648 or email

To read the BGMA Manifesto in full please visit here

About the British Generic Manufacturers Association (BGMA)

  • The BGMA comprises members of the generic manufacturing supply industry, who account for approximately 85% of the total UK generic market by volume.
  • They supply 4 out of 5 drugs used by the NHS.
  • BGMA members include eight of the ten largest medicine suppliers to the NHS.
  • A key feature of the strong generics industry in the UK is that it introduces competition to the supply of prescription medicines, making them more affordable to the NHS and enhancing their availability to patients.
  • According to NHS figures (NHS Digital), more than a billion items are prescribed generically every year. The competition provided by generic medicines saves the NHS around £ 15 billion annually.